Inspira Technologies Oxy BHN (Inspira Technologies Oxy BHN) ROCE % : -112.24% (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Inspira Technologies Oxy BHN ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Inspira Technologies Oxy BHN's annualized ROCE % for the quarter that ended in Jun. 2023 was -112.24%.

Inspira Technologies Oxy BHN ROCE % Historical Data

The historical data trend for Inspira Technologies Oxy BHN's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inspira Technologies Oxy BHN ROCE % Chart

Inspira Technologies Oxy BHN Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-158.71

-82.60

-108.36

Inspira Technologies Oxy BHN Quarterly Data
	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial											-81.19	-204.13	-91.10	-112.24	-

Inspira Technologies Oxy BHN ROCE % Calculation

Inspira Technologies Oxy BHN's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-11.286	/	( ( (16.166 - 1.662)	+	(9.31 - 2.984) )	/ 2 )
	=	-11.286	/	( (14.504	+	6.326)	/ 2 )
	=	-11.286	/	10.415
	=	-108.36 %

Inspira Technologies Oxy BHN's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	-11.056	/	( ( (13.408 - 2.279)	+	(10.84 - 2.268) )	/ 2 )
	=	-11.056	/	( ( 11.129	+	8.572 )	/ 2 )
	=	-11.056	/	9.8505
	=	-112.24 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

Inspira Technologies Oxy BHN (NAS:IINN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Inspira Technologies Oxy BHN ROCE % Related Terms

Thank you for viewing the detailed overview of Inspira Technologies Oxy BHN's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Inspira Technologies Oxy BHN (Inspira Technologies Oxy BHN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Inspira Technologies Oxy BHN Ltd (NAS:IINN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Ha-Tidhar Street, Ra'anana, ISR, 4366504

Website

http://www.inspira-technologies.com

Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.